OBJECTIVE: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. METHOD: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. RESULTS: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. CONCLUSION: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.
OBJECTIVE: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. METHOD: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. RESULTS: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. CONCLUSION: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.
Authors: B Applegate; B B Lahey; E L Hart; J Biederman; G W Hynd; R A Barkley; T Ollendick; P J Frick; L Greenhill; K McBurnett; J H Newcorn; L Kerdyk; B Garfinkel; I Waldman; D Shaffer Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-09 Impact factor: 8.829
Authors: Stephanie L Collins; Frances R Levin; Richard W Foltin; Herbert D Kleber; Suzette M Evans Journal: Drug Alcohol Depend Date: 2005-10-05 Impact factor: 4.492